Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today results from a clinical phase I first-in-human study of the drug candidate ADC-1013 (JNJ-64457107), a human, monospecific, agonistic, IgG1 antibody targeting the co-stimulatory receptor CD40. The study results show that ADC-1013 is generally well tolerated and support further clinical development of ADC-1013 as a mono- or combination therapy. The data will be presented in an oral and poster
Beds matter because we spend a large part of our life sleeping. Demanding M1 laboratory tests were conducted to ensure that Siparila’s glulam bed components were emission-free.The old bed model had become obsolete. It had begun to look to crude with the braces nailed to the underside.
Siparila wanted to solve the problem of its customer Hilding Anders , a major Nordic bed manufacturer. The proposal was to use glulam components instead of solid wood in a continental bed.
However, at the same time, it
